Waldenstrom macroglobulinemia
MONDO:0100280Also known as: Waldenstrom macroglobulinemia, Waldenstrom's macroglobulinemia, Waldenström Macroglobulinemia, Waldenström macroglobulinemia, Waldenstroem's macroglobulinemia, Waldenstrom's macroglobulinaemia, Waldenstrom's syndrome, macroglobulinemia of Waldenstrom
2122 clinical trials for this condition and its sub-types, 136 tagged with Waldenstrom macroglobulinemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Waldenstrom macroglobulinemia
-
Macroglobulinemia, Waldenstrom, 1 2 trials
-
Macroglobulinemia, Waldenstrom, 2 0 trials
-
Double-Drug attack on Hard-to-Treat lymphomas
Disease control Stopped earlyResearchers are testing whether combining two chemotherapy drugs, pralatrexate and romidepsin, is safe and effective for people with lymphoid cancers that have returned or stopped responding to treatment. The trial first finds the highest dose people can tolerate, then gives that…
Phase 1/2 • Sponsor: Jennifer Amengual • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Blood cancer transplant study tests safer GVHD prevention
Disease control Stopped earlyThis phase 2 trial tested two different drug combinations to prevent graft-versus-host disease (GVHD) in 150 people with blood cancers receiving a stem cell transplant from an unrelated donor. Both combinations used cyclosporine and sirolimus, plus either mycophenolate mofetil or…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Cancer drug combo trial halted early: what it means for patients
Disease control Stopped earlyThis study tested a combination of two drugs, ibrutinib and ixazomib, in 21 people with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see if the combo could shrink or control the cancer. The trial was stopped early, so results are limited, but the approach a…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental CAR T-Cell therapy targets rare B-Cell cancers
Disease control Stopped earlyThis phase 2 study tested a treatment called brexucabtagene autoleucel, a CAR T-cell therapy made from a patient's own immune cells, for four rare B-cell cancers: Waldenstrom macroglobulinemia, Richter transformation, Burkitt lymphoma, and hairy cell leukemia. The trial enrolled …
Phase 2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental drug pomalidomide tested in rare blood cancer
Disease control Stopped earlyThis early-phase trial tested the drug pomalidomide in 15 people with Waldenstrom macroglobulinemia, a rare blood cancer that had returned or was not responding to prior treatments. The goal was to find the safest dose and see how the drug affects the immune system and cancer gro…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 14:07 UTC
-
20-Year review of lymphoma care reveals Real-World treatment success
Knowledge-focused Stopped earlyThis study examines the medical records of 400 people diagnosed with various types of lymphoma at a French hospital between 1999 and 2018. Researchers want to see how long patients survived and whether the care they received matched what medical guidelines recommend. The goal is …
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Ibrutinib heart risks under the microscope: can we predict them?
Knowledge-focused Stopped earlyThis study aimed to understand why some people taking the cancer drug ibrutinib develop heart issues like atrial fibrillation (irregular heartbeat) and high blood pressure. Researchers planned to follow 8 patients with blood cancers, using heart tests and blood markers to try to …
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC